BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2969858)

  • 1. Treatment of central precocious puberty with an LHRH agonist (Buserelin): effect on growth and bone maturation after three years of treatment.
    Rappaport R; Fontoura M; Brauner R
    Horm Res; 1987; 28(2-4):149-54. PubMed ID: 2969858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis.
    Styne DM; Harris DA; Egli CA; Conte FA; Kaplan SL; Rivier J; Vale W; Grumbach MM
    J Clin Endocrinol Metab; 1985 Jul; 61(1):142-51. PubMed ID: 3923027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of central precocious puberty with an intranasal analogue of GnRH (Buserelin).
    Bourguignon JP; Van Vliet G; Vandeweghe M; Malvaux P; Vanderschueren-Lodeweyckx M; Craen M; Du Caju MV; Ernould C
    Eur J Pediatr; 1987 Nov; 146(6):555-60. PubMed ID: 3123239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group.
    Partsch CJ; Hümmelink R; Peter M; Sippell WG; Oostdijk W; Odink RJ; Drop SL
    Horm Res; 1993; 39(3-4):111-7. PubMed ID: 8262471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of GnRH analogue (Buserelin) treatment in girls with central precocious puberty.
    Brauner R; Thibaud E; Bischof P; Sizonenko PC; Rappaport R
    Acta Paediatr Scand; 1985 Nov; 74(6):945-9. PubMed ID: 3937430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of central precocious puberty with an LHRH analog. Effect on growth and bone maturation after 2 years of treatment].
    Brauner R; Rappaport R
    Arch Fr Pediatr; 1987 Apr; 44(4):271-6. PubMed ID: 3109347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. Effects on somatic growth and skeletal maturation.
    Mansfield MJ; Beardsworth DE; Loughlin JS; Crawford JD; Bode HH; Rivier J; Vale W; Kushner DC; Crigler JF; Crowley WF
    N Engl J Med; 1983 Nov; 309(21):1286-90. PubMed ID: 6415479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal and subcutaneous treatment of central precocious puberty in both sexes with a long-acting analog of luteinizing hormone-releasing hormone.
    Luder AS; Holland FJ; Costigan DC; Jenner MR; Wielgosz G; Fazekas AT
    J Clin Endocrinol Metab; 1984 Jun; 58(6):966-72. PubMed ID: 6427266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luteinizing hormone releasing hormone analogue therapy for central precocious puberty. Long-term effect on somatic growth, bone maturation, and predicted height.
    Comite F; Cassorla F; Barnes KM; Hench KD; Dwyer A; Skerda MC; Loriaux DL; Cutler GB; Pescovitz OH
    JAMA; 1986 May; 255(19):2613-6. PubMed ID: 3084811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy.
    Pescovitz OH; Comite F; Hench K; Barnes K; McNemar A; Foster C; Kenigsberg D; Loriaux DL; Cutler GB
    J Pediatr; 1986 Jan; 108(1):47-54. PubMed ID: 3080571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules.
    Roger M; Chaussain JL; Berlier P; Bost M; Canlorbe P; Colle M; Francois R; Garandeau P; Lahlou N; Morel Y
    J Clin Endocrinol Metab; 1986 Apr; 62(4):670-7. PubMed ID: 2936759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison between complete and incomplete suppression of the hypophyseal-gonadal axis in girls with central precocious puberty: effect on growth and prospective final height].
    Partsch CJ; Hümmelink R; Sippell WG; Oostdijk W; Odink RJ; Drop SL
    Monatsschr Kinderheilkd; 1993 Dec; 141(12):935-9. PubMed ID: 8114776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone release hormone (D-Tryp6-GnRH) in monthly injections. Its possible use in normal puberty.
    Marcondes JA; Abujamra AC; Minanni SL; Mendonca BB; Nery M; Lerario AC; Pereira MA; Abelin N; Wajchenberg BL
    Horm Metab Res; 1993 Feb; 25(2):105-9. PubMed ID: 8458605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results of long-acting luteinizing-hormone-releasing hormone agonist in central precocious puberty.
    Swaenepoel C; Chaussain JL; Roger M
    Horm Res; 1991; 36(3-4):126-30. PubMed ID: 1840142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of children with central precocious puberty by a slow-release gonadotropin-releasing hormone agonist.
    Oostdijk W; Hümmelink R; Odink RJ; Partsch CJ; Drop SL; Lorenzen F; Sippell WG; van der Velde EA; Schultheiss H
    Eur J Pediatr; 1990 Feb; 149(5):308-13. PubMed ID: 2138079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin.
    Laue L; Jones J; Barnes KM; Cutler GB
    J Clin Endocrinol Metab; 1993 Jan; 76(1):151-5. PubMed ID: 8421081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
    Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF
    Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luteinizing hormone-releasing hormone analog treatment of boys with hypothalamic hamartoma and true precocious puberty.
    Comite F; Pescovitz OH; Rieth KG; Dwyer AJ; Hench K; McNemar A; Loriaux DL; Cutler GB
    J Clin Endocrinol Metab; 1984 Nov; 59(5):888-92. PubMed ID: 6434587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height.
    Lazar L; Pertzelan A; Weintrob N; Phillip M; Kauli R
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4127-32. PubMed ID: 11549638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.